BioNTech Current Deferred Revenue from 2010 to 2024
| BNTX Stock | USD 108.23 6.09 5.96% |
Current Deferred Revenue | First Reported 2018-12-31 | Previous Quarter 361.3 M | Current Value 236 M | Quarterly Volatility 180.3 M |
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many indicators such as Price To Sales Ratio of 5.77, Dividend Yield of 0.0111 or PTB Ratio of 1.2. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
BioNTech | Current Deferred Revenue |
Latest BioNTech's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of BioNTech SE over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. BioNTech's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
BioNTech Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 123,547,800 | |
| Geometric Mean | 76,156,153 | |
| Coefficient Of Variation | 109.33 | |
| Mean Deviation | 108,094,373 | |
| Median | 66,027,000 | |
| Standard Deviation | 135,070,534 | |
| Sample Variance | 18244T | |
| Range | 358.1M | |
| R-Value | 0.75 | |
| Mean Square Error | 8572.6T | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | 22,675,721 | |
| Total Sum of Squares | 255416.7T |
BioNTech Current Deferred Revenue History
About BioNTech Financial Statements
BioNTech investors use historical fundamental indicators, such as BioNTech's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 353.3 M | 371 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.